A phase I/II study of dasatinib in relapsed or refractory non-Hodgkin's lymphoma (NHL) (BMS [Bristol-Myers Squibb] protocol 180129).
Latest Information Update: 28 Sep 2023
At a glance
- Drugs Dasatinib (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 30 Jan 2019 Status changed from active, no longer recruiting to completed.
- 15 Aug 2017 Planned End Date changed from 1 Sep 2015 to 1 May 2018.
- 15 Aug 2017 Planned primary completion date changed from 1 Sep 2015 to 1 Apr 2018.